CBX-250: A First-in-Class TCR-Mimetic-Based T-Cell Engager for the Treatment of Myeloid Leukemia

Time: 4:05 pm
day: Conference Day Two


  • Introduce a novel TCR-mimetic based T-cell engager against a novel target in AML and other myeloid malignancies
  • Discuss the preclinical characterization strategy and results of target safety, binder potency, binder specificity and TCE developability